Latest Pacific Markets News

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Jatcorp Limited reported a strong 36% revenue increase to $23 million for the half-year ended December 2025, narrowing its net loss and expanding its footprint across Asia Pacific markets despite ongoing legal challenges in China.

BSP Financial Group has reported a robust 12.9% increase in net profit for 2025, underpinned by strong revenue growth and strategic restructuring, including converting its Fiji branch into a wholly owned subsidiary.

X2M Connect Limited reported a robust first half of FY26 with a 45% revenue increase and significant contract wins in Asia, positioning the company for sustained growth.

OpenLearning Limited reported a robust Q4 FY25 with SaaS annual recurring revenue growing 30% year-on-year to $3.035 million, underpinned by $3.6 million in new contracts across key Asia-Pacific markets. The company’s AI-powered learning management system continues to gain traction internationally as it targets cash flow breakeven by early 2027.

ReNerve Limited has secured market approval for its NervAlign® Nerve Cuff in Malaysia, marking a key milestone in its Asia-Pacific expansion strategy. This approval follows earlier clearances in Hong Kong and Thailand, positioning the company to tap into a growing regional nerve repair market.

SunRice reported a 14% rise in net profit for the first half of FY26 despite a revenue dip, reaffirming its growth outlook and updating paddy price guidance amid a forecast drier season.

Ricegrowers Limited (SunRice) reported a 14.5% rise in half-year profit despite a 3.1% revenue decline, driven by improved margins and strategic growth in key markets. The company also increased its interim dividend by a third, signaling confidence in its 2030 Growth Strategy.

NEXTDC has reported a significant 29% increase in contracted utilisation to 316MW, prompting a $400 million rise in FY26 capital expenditure guidance to support accelerated capacity expansion.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Zeotech Limited has locked in a $204 million binding offtake agreement for its kaolin products and successfully demonstrated its AusPozz™ low-carbon metakaolin in a large-scale concrete pour, signaling strong momentum in its commercialisation efforts.